Drug Patents owned by Rvl Pharms

1. List of Upneeq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912765 RVL PHARMS Compositions and methods for non-surgical treatment of ptosis
Aug, 2031

(8 years from now)

US9867808 RVL PHARMS Compositions and methods for non-surgical treatment of Ptosis
Aug, 2031

(8 years from now)

US8357714 RVL PHARMS Compositions and methods for non-surgical treatment of ptosis
Aug, 2031

(8 years from now)

US10814001 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US10898573 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US11103482 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US11324722 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(16 years from now)

US11311515 RVL PHARMS Oxymetazoline compositions
Dec, 2039

(16 years from now)

US11541036 RVL PHARMS NA
Dec, 2039

(16 years from now)

US10940138 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(16 years from now)

US10799481 RVL PHARMS Compositions and methods for treating ocular disorders
Dec, 2039

(16 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 8, 2023

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 08 July, 2020

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in